ESMO 2019 annual Congress
Programme du congrès
ESMO 2019 Highlights in HER2 negative advanced gBRCA associated breast cancer: The BROCADE3 study
- Date : 01/10/2019
- 1 0
PAOLA-1 Phase 3 data: olaparib plus bevacizumab maintenance for advanced ovarian cancer
- Date : 27/09/2019
- 1 0
IMvigor130: atezolizumab +/- platinum-based chemo upfront for advanced urothelial carcinoma
- Date : 27/09/2019
- 1 0
ESMO 2019: Dr. Mirza on Important Trials with PARP Inhibitors in Ovarian Cancer
- Date : 01/10/2019
- 0 0
ESMO 2019 Expert Video Report on immune checkpoint inhibitors in MSI-High tumours
- Date : 01/10/2019
- 0 0
ESMO 2019 Highlights in metastatic castration resistant prostate cancer: The PROFOUND study
- Date : 01/10/2019
- 0 0
ESMO 2019 Highlights in HR+ HER2? advanced breast cancer: The MONALEESA-3 study
- Date : 01/10/2019
- 0 0
ESMO 2019 Highlights in advanced non small cell lung cancer: The CheckMate 227 study
- Date : 01/10/2019
- 0 0
Initial EV-103 results: enfortumab vedotin plus pembrolizumab for urothelial carcinoma
- Date : 27/09/2019
- 0 0
No clear evidence for benefit with addition of Rova-T to chemo for extensive SCLC
- Date : 27/09/2019
- 0 0
Encouraging phase 3 CheckMate 238 data: adjuvant nivolumab in resected stage III/IV melanoma
- Date : 27/09/2019
- 0 0
Long-term outcomes of nivo vs. nivo/ipi in melanoma brain metastases: ABC trial data
- Date : 27/09/2019
- 0 0
FIGHT-202 data: pemigatinib for previously treated locally advanced/metastatic cholangiocarcinoma
- Date : 27/09/2019
- 0 0
OpACIn-neo trial RFS and biomarker analyses: optimal neoadjuvant ipi/nivo dosing in melanoma
- Date : 27/09/2019
- 0 0
MONALEESA-3 OS results: fulvestrant/ribociclib in postmenopausal HR+/HER2- advanced breast cancer
- Date : 27/09/2019
- 0 0
Phase 3 KEYNOTE-522 results: pembro/chemo neoadjuvant, pembro adjuvant in early TNBC
- Date : 27/09/2019
- 0 0
MONARCH 2: abemaciclib added to fulvestrant shows OS benefit in HR+/HER2- advanced breast cancer
- Date : 27/09/2019
- 0 0
BYLieve additional cohort: update on the trial of alpelisib in advanced breast cancer from ESMO
- Date : 27/09/2019
- 0 0
Adding alpelisib for HR+/HER2- advanced breast cancer in SOLAR-1: adverse event impacts
- Date : 27/09/2019
- 0 0
Blood first assay screening in treatment-naïve NSCLC: initial results from the ALK+ cohort
- Date : 27/09/2019
- 0 0
Twitter oncology networks: interview with @weoncologists on the @OncoAlert movement
- Date : 27/09/2019
- 0 0
PROfound performance: olaparib vs. enzalutamide or abiraterone for HRR altered mCRPC
- Date : 27/09/2019
- 0 0
One to watch: KEYNOTE-866, perioperative pembro with neoadjuvant chemo in MIBC
- Date : 27/09/2019
- 0 0
Phase 3 IMvigor130 results: atezolizumab in untreated metastatic urothelial carcinoma
- Date : 27/09/2019
- 0 0
Lurbinectedin monotherapy is active in progressive malignant pleural mesothelioma: SAK 17/16 results
- Date : 27/09/2019
- 0 0
FORWARD I: mirvetuximab soravtansine vs chemo in platinum-resistant ovarian cancer
- Date : 27/09/2019
- 0 0
GAP study: nab-paclitaxel & gemcitabine in locally advanced, unresectable pancreatic cancer
- Date : 27/09/2019
- 0 0
Updates on HPV+ oropharyngeal cancer - de-escalation and reducing costs with cisplatin
- Date : 27/09/2019
- 0 0
Urothelial carcinoma: apatorsen plus docetaxel does not provide significant value
- Date : 27/09/2019
- 0 0
Sélection de congrès
14èmes Journées des Référentiels en Soins Oncologiques de support - AFSOS 2024
- Date : 12/12/2024
-
2514
0
45emes Journées de la Société Française de Sénologie et de Pathologie Mammaire - SFSPM 2024
- Date : 06/11/2024
-
5211
0